HER2-Negative Breast Cancer Intelligence: Oct'22

In support of Breast Cancer Awareness month, Ferma.AI is here with a snapshot of HER2-negative Breast Cancer clinical trials intelligence from October, 2022.

Here is an overview of key events during the month.

9 new trials introduced

Stemline Therapeutics | Elacestrant; Alpelisib; Everolimus; Ribociclib; Palbociclib | Advanced ER-Positive HER2-Negative Metastatic Breast Cancer | Phase 1/2 | Primary Endpoint: RP2D

Pfizer | ARV-471; Ribociclib | ER-Positive HER2-Negative Advanced or Metastatic Breast Cancer | Phase 1/2 | Primary Endpoints: DLTs, OR

Ellipses Pharma | EP0062 | Relapsed Locally Advanced or Metastatic AR-Positive HER2-Negative ER-Positive Breast Cancer | Phase 1/2 | Primary Endpoints: DLTs, MTD, AE

ProfoundBio | PRO1184 | Locally Advanced and/or Metastatic HR+ HER2-negative Breast Cancer; Locally Advanced and/or Metastatic ST (Ovarian Cancer; Endometrial Cancer; NSCLC; TNBC; Mesothelioma) | Phase 1/2 | Primary endpoints: DLTs, TEAEs

Stemline Therapeutics | Elacestrant | CDK4/6i-Naive ER-positive HER2-negative Advanced Metastatic Breast Cancer | Phase 2 | Primary endpoint: PFS  

143 trials modified

  • NCT05306340 (evERA Breast Cancer): The trial sponsored by Genentech has the following updates:

     - Outcome measures will be determined in both ESR1m subpopulation                     and ITT population

     - TTCD in pain severity has been added as a secondary outcome measure

      - Criteria has been updated to include unresectable patient population

  • NCT04192331: Study type has been changed from observational to a phase 2 interventional study with randomized allocation and parallel assignment interventional model
  • NCT03328026: One of the combination drugs, Epacadostat, will not be considered as an intervention. Expansion cohort will be randomized into two arms with differences in initial treatment sequences
  • NCT04683679: The trial sponsored by Memorial Sloan Kettering Cancer Center has the following updates,

        - ER-Positive/Her2-negative BC patients will also be enrolled in the study           along with the TNBC population

      - Allocation has been changed to non-randomized and a new arm (Arm C)             was added to the trial, which includes ER-positive mBC patients treated               with pembrolizumab, SBRT and Olaparib

      - The study was amended to pause Arm B

6 Press Releases and 18 News Articles

  • Gilead's sBLA application for Trodelvy was accepted for priority review by the FDA for adult unresectable locally advanced HR-positive HER2-negative mBC based on the results from the phase 3 TROPiCS-02 study. PDUFA target action date is currently set for February 2023. Source: Gilead, 11-Oct-2022
  • An analysis from the PALLAS trial presented during the 2022 ASCO Plenary Series, demonstrated that addition of palbociclib to endocrine therapy did not prolong iDFS in patients with ER+/ HER2- early BC. Also, secondary endpoints failed to improve. Source:Onclive, 20-Oct-2022
  • FDA authorized the initiation of the first Phase 2 study of Atossa’s proprietary (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer thereby lifting the clinical hold. Source: AtossaTherapeutics, 24-Oct-2022
  • Preliminary results of the phase 3 CAPItello-291 trial showed that capivasertib plus fulvestrant generated a statistically significant improvement in PFS, thereby meeting its primary endpoint in patients with HR-positive, HER2-low or negative locally advanced or mBC. Source: Astrazeneca, 26-Oct-2022
  • Updated results from the phase 2 SERENA-II trial showed that camizestrant led to a statistically significant improvement in PFS when compared to fulvestrant in advanced ER-positive HER2-negative BC. Source: Astrazeneca, 26-Oct-2022
  • Preliminary results from a Phase 1/2 trial, NCT04505826 presented at 34th EORTC-NCI-AACR Symposium highlighted that OP-1250-001 had favorable tolerability, high drug exposure and strong anti-tumor activity in advanced ER-positive, HER2-negative mBC. Source: Olema Oncology, 26-Oct-2022

21 Publications from Pubmed and ScienceDirect

  • PMID: 36194623: Assessing sacituzumab govitecan in HR+/HER2- breast cancer (News in Brief)
  • ScienceDirect: Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early BC. Geyer Jr. et al.
  • PMID: 36207609: Outcomes of patients with HER2-negative mBC after first-line chemotherapy among patients with and without pathogenic gBRCA1/2 mutations. Jacot et al.
  • PMID: 36239405: Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR+/HER2- advanced BC: Safety analysis of the randomized PARSIFAL trial. Cosimo et al.

Social Analysis

  • 17 LinkedIn posts, 5 Facebook posts, 1 Instagram post and 2 tweets collectively highlighted that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental biologics license application (sBLA) for sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.

This sBLA is based on data from the registrational phase 3 TROPiCS-02 clinical trial (NCT03901339), which met its primary endpoint of progression-free      survival (PFS) and key secondary endpoint of overall survival (OS) compared to physician’s choice of chemotherapy.

  • 2 LinkedIn posts, 1 Facebook, 1 Instagram post and 1 tweet discussed the second interim analysis results of OlympiA clinical trial (NCT02032823) and mentioned that, with 3.5 years of median follow-up, OlympiA demonstrated statistically significant improvement in overall survival (OS) with adjuvant olaparib compared with placebo for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 and high-risk, HER2-negative early breast cancer. The findings were published in the Annals of Oncology journal on 10th October 2022
  • 10 tweets, 2 LinkedIn posts and 2 Facebook posts collectively highlighted the results from ELAINE- 2 clinical trial (NCT04432454) and stated that lasofoxifene, when combined with abemaciclib (Verzenio), a CDK 4/6 inhibitor, demonstrated promising clinical activity and had a favorable risk-to-benefit ratio for the treatment of pre- and postmenopausal patients with ER-positive/HER2-negative metastatic breast cancer who harbor an ESR1 mutation and whose disease had progressed on prior therapies
  • 3 LinkedIn posts, 3 Facebook posts, 1 Reddit post and 1 tweet collectively highlighted the announcement by Atossa Therapeutics and mentioned that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and authorized initiation of the phase 2 neoadjuvant clinical study of (Z)-endoxifen in premenopausal women with early-stage estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This is the first study of Atossa’s proprietary (Z)-endoxifen in the United States
  • 3 LinkedIn posts, 1 Facebook post and 1 Instagram post discussed the positive high-level results from the CAPItello-291 Phase III trial and mentioned that AstraZeneca’s capivasertib (AZD5363) in combination with fulvestrant (Faslodex) showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with placebo plus fulvestrant in patients with hormone receptor (HR)-positive, HER2-low or negative locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy

Ferma.AI is an AI-driven platform specialized at collecting and synthesizing custom insights from large volumes of data. If would like to receive similar weekly intelligence snapshots, please leave your information below.

Thanks for your interest.

We have received your information and member of our team will be in touch with you shortly.